<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
<url><loc>https://insightsemerge.com/press-releases/ambrosia-biosciences-announces-the-nonclinical-data-profiles-of-two-oral-small-molecule</loc><news:news><news:publication><news:name>Insights Emerge</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15T14:26:04.464Z</news:publication_date><news:title>Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist</news:title></news:news></url>
<url><loc>https://insightsemerge.com/press-releases/lilly-to-present-new-data-across-zepbound-foundayo-eloratzp-and-retatrutide-at</loc><news:news><news:publication><news:name>Insights Emerge</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14T17:13:29.209Z</news:publication_date><news:title>Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale</news:title></news:news></url>
<url><loc>https://insightsemerge.com/press-releases/innovent-announces-seven-innovative-products-including-mazdutide-and-pecondler</loc><news:news><news:publication><news:name>Insights Emerge</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-14T04:09:16.524Z</news:publication_date><news:title>Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List</news:title></news:news></url>
</urlset>